ImmunoGen Inc. (Nasdaq: IMGN) announced that development partner Roche reported disappointing Phase III MARIANNE study results for three HER2-targeted regimens to treat HER2-positive metastatic breast cancer. Shares of the biotechnology company plummeted $4.74 to close at $6.11.